| Overview |
| bsm-33077m |
| CD5 Monoclonal Antibody |
| WB, IHC-P, IHC-F, IF, Flow-Cyt |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| KLH conjugated synthetic peptide derived from human CD5 |
| Monoclonal |
| 12A8 |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 921 |
| P06127 |
| Cell membrane |
| T-cell surface glycoprotein CD5; Lymphocyte antigen 1; Ly-1; Lyt-1; CD-5; CD5 antigen; CD 5; CD5 molecule; CD5 antigen (p56 62); CD5_HUMAN; LEU 1; LEU1; Ly12; LyA; Lymphocyte Antigen CD5; Lymphocyte antigen T1/Leu 1; Lymphocyte antigen T1/Leu-1; Lymphocyte glycoprotein T1/Leu1; OTTHUMP00000236973; p56 62; T1. |
| This gene encodes a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. This protein also plays a role in signal transduction pathways in the activation of T cells. Mutations in this gene cause CD59 deficiency, a disease resulting in hemolytic anemia and thrombosis, and which causes cerebral infarction. Multiple alternatively spliced transcript variants, which encode the same protein, have been identified for this gene. [provided by RefSeq, Jul 2008] |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF |
|
| Flow-Cyt |
1ug/Test |